Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong
出版年份 2022 全文链接
标题
Three-dose vaccination-induced immune responses protect against SARS-CoV-2 Omicron BA.2: a population-based study in Hong Kong
作者
关键词
-
出版物
The Lancet Regional Health Western Pacific
Volume 32, Issue -, Pages 100660
出版商
Elsevier BV
发表日期
2022-12-24
DOI
10.1016/j.lanwpc.2022.100660
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
- (2022) Alexandra C. Walls et al. CELL
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
- (2022) Emma K. Accorsi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea
- (2022) Min-Kyung Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- Characteristics of the first 1119 SARS‐CoV‐2 Omicron variant cases, in Marseille, France, November−December 2021
- (2022) Linda Houhamdi et al. JOURNAL OF MEDICAL VIROLOGY
- Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study
- (2022) Nicole Wolter et al. LANCET
- Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
- (2022) Sue Ann Costa Clemens et al. LANCET
- Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
- (2022) Huiping Shuai et al. NATURE
- SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
- (2022) Kenrie P. Y. Hui et al. NATURE
- Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
- (2022) Thiago Cerqueira-Silva et al. NATURE MEDICINE
- Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
- (2022) Yu Gao et al. NATURE MEDICINE
- Neutralizing antibodies against the SARS-CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2 vaccination
- (2022) Samuel M. S. Cheng et al. NATURE MEDICINE
- Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination
- (2022) Eddy Pérez-Then et al. NATURE MEDICINE
- Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022
- (2022) Mark G. Thompson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Vaccine‐breakthrough infection by the SARS‐CoV‐2 omicron variant elicits broadly cross‐reactive immune responses
- (2022) Runhong Zhou et al. Clinical and Translational Medicine
- Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
- (2022) Rishi R. Goel et al. CELL
- Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Subvariant BA.2 in a Single-Source Community Outbreak
- (2022) Vincent Chi-Chung Cheng et al. CLINICAL INFECTIOUS DISEASES
- The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants
- (2022) Marios Koutsakos et al. IMMUNITY
- Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study
- (2022) Cristina Menni et al. LANCET
- Antibody evasion properties of SARS-CoV-2 Omicron sublineages
- (2022) Sho Iketani et al. NATURE
- T cell responses to SARS-CoV-2 spike cross-recognize Omicron
- (2022) Roanne Keeton et al. NATURE
- Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost
- (2022) Frauke Muecksch et al. NATURE
- Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial
- (2022) Laurence Chu et al. NATURE MEDICINE
- Protection with a Third Dose of mRNA Vaccine against SARS-CoV-2 Variants in Frontline Workers
- (2022) Sarang K. Yoon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
- (2022) Jingyou Yu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
- (2022) Qiaoli Peng et al. EBioMedicine
- Omicron BA.1 breakthrough infection drives cross-variant neutralization and memory B cell formation against conserved epitopes
- (2022) Jasmin Quandt et al. Science Immunology
- Recall of pre-existing cross-reactive B cell memory following Omicron BA.1 breakthrough infection
- (2022) Chengzi I. Kaku et al. Science Immunology
- Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?
- (2022) Menno C. van Zelm Science Immunology
- COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron
- (2022) Nungruthai Suntronwong et al. Vaccines
- Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
- (2022) Aekkachai Tuekprakhon et al. CELL
- Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study
- (2022) Martina E McMenamin et al. LANCET INFECTIOUS DISEASES
- Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
- (2022) Qian Wang et al. NATURE
- BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
- (2022) Yunlong Cao et al. NATURE
- Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variants
- (2022) João Malato et al. NEW ENGLAND JOURNAL OF MEDICINE
- Replication of SARS-CoV-2 Omicron BA.2 variant in ex vivo cultures of the human upper and lower respiratory tract
- (2022) Kenrie P.Y. Hui et al. EBioMedicine
- Adaptive immunity to SARS-CoV-2 and COVID-19
- (2021) Alessandro Sette et al. CELL
- Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies
- (2021) Dongyan Zhou et al. Cell Host & Microbe
- Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
- (2021) Laith J. Abu-Raddad et al. NEW ENGLAND JOURNAL OF MEDICINE
- SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model
- (2021) Bart L Haagmans et al. JOURNAL OF INFECTIOUS DISEASES
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey
- (2021) Mine Durusu Tanriover et al. LANCET
- Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves
- (2021) Caroline Maslo et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials
- (2021) Gang Zeng et al. LANCET INFECTIOUS DISEASES
- Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
- (2021) Rima Moghnieh et al. VACCINE
- Acute SARS-CoV-2 Infection Impairs Dendritic Cell and T Cell Responses
- (2020) Runhong Zhou et al. IMMUNITY
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
- (2020) Nina Le Bert et al. NATURE
- Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19
- (2020) Jennifer A. Juno et al. NATURE MEDICINE
- Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
- (2020) Shengli Xia et al. LANCET INFECTIOUS DISEASES
- SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
- (2020) Christopher O. Barnes et al. NATURE
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
- (2020) Lindsey R. Baden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started